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Background
Type IV drug hypersensitivity reactions with cutaneous
manifestations (cADR) are highly variable in clinical
appearance and degree of severity, ranging from maculo-
papular exanthema (MPE) to more severe disorders such
as DRESS or SJS/TEN. Recent studies show NKp46+
cells in skin of drug-induced exanthemas, and NK cells
expressing granulysin have been found in blister fluids
from SJS/TEN patients, suggesting that NK cells can con-
tribute to keratinocyte killing as well as CTLs. The bal-
ance of activating and inhibitory signals delivered by
innate NK receptors determines the activity of NK cells.
Among activating receptors, NKG2D is expressed in the
cell membrane of NK cells and CTLs as a homodimer
associated to the molecule DAP-10, which transduces the
activating signal through the activation of PI-3 kinase.
NKG2D ligands are HLA class I-like molecules MICA
and MICB, and UL-16 binding proteins (ULBP). Their
expression is upregulated in stress conditions.
Objective
To explore the involvement of the activating receptor
NKG2D in cADR.
Methods
Quantitative RT- PCR was performed in skin biopsies
from healthy donors, MPE, DRESS, and SJS/TEN patients
to evaluate the expression of DAP-10, and NKG2D
ligands (MICA, MICB and ULBP1-3). Degranulation
assays were performed to investigate NKG2D-dependent
activity in lymphocytes from blister fluids.
Results
DAP-10 mRNA levels were found to be significantly
increased in biopsies from DRESS patients compared to
MPE and healthy skin. Nonetheless, the highest mRNA
levels were detected in SJS/TEN biopsies. Among the
five NKG2D ligands analyzed, only MICA and ULBP1
mRNA were identified in skin biopsies, and both were
significantly upregulated in skin form SJS/TEN patients.
Degranulation assays against NKG2D ligand-expressing
cell lines revealed no NKG2D-driven cytolitic activity in
CTLs and increased cytotoxicity by blister fluid NK cells
compared to NKG2D ligand negative cells.
Conclusion
DAP-10 mRNA levels suggest increased activity of NKG2D
in lymphocytes infiltrating the skin in DRESS and SJS/TEN
patients. However, the pattern of expression of NKG2D
ligands indicates that NKG2D-dependen cytolytic activity
might be more relevant in bullous diseases. Moreover,
degranulation assays confirm NKG2D-dependen activity in
blister fluid NK cells and suggest that NKG2D might be an
activating receptor involved in keratinocyte killing by NK
cells in SJS/TEN.
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